A new clinical research program has been launched in Israel that will trial cannabinoid-based IBD treatment and other products from Israel’s SciCann. The program partners SciCann with Canada’s FSD and Mor – the technology transfer arm of Israel’s Clalit HealthCare.

https://www.prnewswire.com/news-releases/fsd-pharma-and-scicann-therapeutics-launch-clinical-research-program-in-israel-300698081.html

https://www.prnewswire.com/news-releases/fsd-pharma-reports-positive-pre-clinical-results-for-proprietary-cbd-combination-product-300701239.html